Image

Medi Oasis believes in Pharmacogenomics. We have partnered with companies to expand its reach.

Image

Over 4 billion prescriptions are issued each year.  However, not all drugs are effective for all people. In fact, response rates for many drugs are only between 50-75%.  Adverse drug reactions (ADRs) account for up to 7% of all hospital admissions and up to 20% of re-admissions, according to estimates.  ADRs are the fourth leading cause of death and are estimated to cost $136 billion annually. An estimated 10-20% of ADRs may be due to genetic factors.

Pharmacogenomics aims to develop rational means to optimize drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects.Through the utilization of pharmacogenomics, it is hoped that pharmaceutical drug treatments can deviate from what is dubbed as the "one-dose-fits-all" approach. Pharmacogenomics also attempts to eliminate the trial-and-error method of prescribing, allowing physicians to take into consideration their patient's genes, the functionality of these genes, and how this may affect the efficacy of the patient's current or future treatments (and where applicable, provide an explanation for the failure of past treatments). Such approaches promise the advent of precision medicine and even personalized medicine, in which drugs and drug combinations are optimized for narrow subsets of patients or even for each individual's unique genetic makeup. Whether used to explain a patient's response or lack thereof to a treatment, or act as a predictive tool, it hopes to achieve better treatment outcomes, greater efficacy, minimization of the occurrence of drug toxicities and adverse drug reactions (ADRs). For patients who have lack of therapeutic response to a treatment, alternative therapies can be prescribed that would best suit their requirements. In order to provide pharmacogenomic recommendations for a given drug, two possible types of input can be used: genotyping or exome or whole genome sequencing.  Sequencing provides many more data points, including detection of mutations that prematurely terminate the synthesized protein (early stop codon).  Medi Oasis recently ended a government clinical trial with Component DX.

© 2013-2020 Medi Oasis Health Services LLC 

Press enter to search
Press enter to search

 Office: (+1) 203-659-2693

Fax:     (+1) 203-659-2694

Email: 

info@medioasishealthservices.com 

billing@medioasishealthservices.com

New Office Location:

30 Old Kings Highway South, Darien, CT 06820

Opening Hours

Mon - Fri
9:00 am to 7:00 pm
Saturday
9:00 am to 2:00 pm
Sunday
Closed

CEO's Words

"The future begins with a conscious effort to help people."

A.Givans

Get Connected